Navigation Links
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Date:11/11/2008

ne year of angioplasty, and of heart failure and death following a heart attack. Prospective, randomized, clinical trials have demonstrated that the rate of heart attack in Hp2-2 diabetes can be decreased by the administration of natural vitamin E (400IU).

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical test to identify patients with Hp2-2 diabetes. This test, or a similar genetic form of the test, may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics'
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
5. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
6. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
10. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
11. Synvista Therapeutics to be Featured on Wallst.net
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... 4MD Medical ... Women’s Association, offering an exclusive scholarship opportunity for women across the country to earn ... individual as they continue their education,” said Rochelle Schwartz, Founder of 4MD Medical and ...
(Date:7/7/2015)... 7, 2015  Neogen Corporation (NASDAQ: NEOG ) ... expand its relationship with Illumina (NASDAQ: ILMN ), ... agreement, Illumina will market and sell arrays with Neogen,s ... BeadArray technology, to the global agrigenomics community. ... its GeneSeek ® genomics laboratory in ...
(Date:7/7/2015)... ... July 07, 2015 , ... uBiome, the leading microbial genomics company, is offering ... kits and full 16S laboratory analysis. The goal is to fast-track a study with ... access to their own dashboard, enabling them to view and compare the results of ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... CSM, a ... team as Vice President of Finance. Morse has an extensive background in financial management ... to the CSM team. In his new role, Morse will oversee all financial areas ...
Breaking Biology Technology:4MD Medical Announces $2,000 Scholarship Opportunity in Conjunction with American Business Women’s Association (ABWA) 24MD Medical Announces $2,000 Scholarship Opportunity in Conjunction with American Business Women’s Association (ABWA) 3Neogen signs commercialization agreement with Illumina 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3CSM Appoints Michael Morse as Vice President of Finance 2
... 9 Kendle (Nasdaq: KNDL ), ... announced Chief Operating Officer Christopher Bergen will participate ... March 10 as well as the Raymond James ... http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ) Barclays ...
... Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged ... announced that the U.S. Food and Drug Administration (FDA) ... Adhesion Barrier for use in pediatric cardiac surgery patients. ... over the surface of the heart at the conclusion ...
... Alliance, the leading management consulting firm specializing in ... Joe Dillon has joined its Business Development Practice. ... Business Development Practice to help pharmaceutical and biotech ... related to in- and out-licensing, opportunity assessment, and ...
Cached Biology Technology:Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 3Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 2Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 3
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... A recently released scientific paper authored by San ... leading causes of death of the endangered California condor ... being the primary factor in juvenile and adult birds. ... California condors at all release sitesCalifornia, Arizona and Baja, ...
... new way to create electromagnetic Terahertz (THz) waves or T-rays ... the study, published recently in the journal Nature Photonics ... T-rays could be used to make better medical scanning gadgets ... ,tricorder, scanner used in Star Trek. In the study, ...
... Jan. 20, 2012   Cell Therapeutics, Inc. ("CTI") (NASDAQ ... the European Medicines Agency,s ("EMA") Committee for Medicinal Products ... opinion on CTI,s Marketing Authorization Application ("MAA") for Pixuvri ... work with the CHMP on the Summary of Product ...
Cached Biology News:Scientific paper shows California condor still threatened by human activities 2T-rays technology could help develop Star Trek-style hand-held medical scanners 2T-rays technology could help develop Star Trek-style hand-held medical scanners 3Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 2Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 3
HSV 1 IgG...
HSV 1 IgM...
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
UBN-1 (C-20)...
Biology Products: